Omega-3 capsules do not prevent cardiovascular disease and increase the risk of atrial fibrillation; Elawady rejects omega-3 capsules.

Original statement

حين أُخضعت المكملات الفموية الأكثر مبيعاً — من الكالسيوم والبيتا كاروتين وفيتامين E، إلى أوميغا-3 والمتعددات والجلوكوزامين والسيلينيوم وفيتامين A — لاختبارات عشوائية مضبوطة بالغفل وبأحجام كبيرة ومتابعة طويلة، لم تَفِ في الغالب بوعودها؛ بل أن بعضها أحدث ضرراً صريحاً: زيادة في الوفيات، وفي سرطان الرئة والبروستاتا، وفي احتشاء عضلة القلب، وفي الرجفان الأذيني، وفي كسور الورك، وفي حصى الكلى. ما يُسوَّق على أنه «وقاية» انقلب في عدة تجارب إلى مصدر للأذى. | حذّر بشدة من المكملات الغذائية الفموية، معتبرًا إياها غير ضرورية وقد تضر الكبد، وشدد على أن التغذية السليمة هي الأساس… ويرفض المكملات الغذائية وبروتين مصل اللبن (واي بروتين)، ومكملات الكولاجين والكرياتين والأوميجا 3.

not verbatim – paraphrase. Translation by the project; the Arabic wording is authoritative.

Translation

Omega-3 capsules do not prevent cardiovascular disease and increase the risk of atrial fibrillation; Elawady rejects omega-3 capsules.

Origin

Source status

Archive editors

Attribution

Archive editors (eltayebat.com); not verified as Elawady's own words

Origin

https://eltayebat.com/rule/oral-supplements/

Attribution uncertainty

Written by the archive operators; study selection is the archive's, not necessarily Elawady's.

Claimed mechanism

Not specified.

Claimed health effect

No CV benefit; more atrial fibrillation.

Population concerned

Adults with or without CVD.

Geographic restriction by Elawady

none found

Diverging source versions

Scientific assessment

Mostly true – Correct at its core, but with limitations or minor inaccuracies.

Certainty of evidence: moderate – Further research may still affect the assessment.

1. What was claimed?

Omega-3 pills don't work and cause AF.

2. What is demonstrably correct?

VITAL HR 0.92 (0.80–1.06), ASCEND RR 0.97 (0.87–1.08), STRENGTH HR 0.99, Alpha Omega HR 1.01 – all non-significant; AF risk increased (Gencer 2021).

3. What is wrong or exaggerated?

Not entirely 'no benefit': Cochrane 2020 reported RR 0.91 (0.85–0.97) for CHD events (low certainty), VITAL showed fewer total MIs (HR 0.72, secondary end point), and REDUCE-IT showed a 25% relative reduction in high-risk patients. AF risk with ≤1 g/day was small (HR 1.12).

4. What remains unclear?

Role of placebo choice (mineral oil vs corn oil) in high-dose trials.

5. Which studies support it?

A-SUP-07, A-SUP-08, A-SUP-09, A-SUP-10, A-SUP-11.

6. Which studies contradict it?

A-SUP-12 (Cochrane small CHD benefit), REDUCE-IT (I-SUP-09).

7. What applies to Germany and Europe?

Applies equally.

8. What is known about Egypt?

Applies equally.

9. What practical conclusion is appropriate?

Over-the-counter fish-oil capsules are not needed for heart protection in most people; prescription EPA may be indicated in specific high-risk patients.

Assessment details

Rationale for certainty of evidence

Large RCTs at ~1 g/day (VITAL, ASCEND, Alpha Omega) and high-dose STRENGTH found no significant reduction in major CV events; meta-analysis of 7 RCTs found AF HR 1.25 (1.07–1.46), larger at >1 g/day. However, the Cochrane review (86 RCTs) found small reductions in coronary heart disease mortality and events (low certainty), and REDUCE-IT (4 g/day icosapent ethyl) reduced events by 25% in high-risk statin-treated patients (debate about mineral-oil placebo not covered by the abstract).

Source quality

Archive cites the null trials and the AF meta-analysis correctly; omits positive findings.

Regional transferability

High.

Individual exceptions

Prescription EPA in hypertriglyceridaemia is an established exception.

Regional scope of the claim

general (biological/medical)

Last reviewed

26 October 2026 provisional

Scientific evidence in detail

True only under certain conditions – The claim holds only for certain doses, groups of people, preparations or circumstances.

Research question: In adults with or without CVD, do omega-3 capsules, compared with placebo, fail to prevent CVD and increase atrial fibrillation?

Study results as reported by the authors. Our assessment follows below.

How deeply was this checked?

9 linked studies: 0 checked in full text (0 of them with a structured risk-of-bias assessment), 9 on the basis of the abstract, 0 bibliographically only. No formal assessment with two independent reviewers and no independent human expert review has taken place yet.

Last scientific review: 26 October 2026

In plain language

Big trials of fish-oil capsules in ordinary doses did not prevent heart attacks or strokes, and they slightly increased an irregular heartbeat called atrial fibrillation. A high-dose prescription form helped some high-risk patients in one large trial. For most people, the capsules are not needed.

Studies on this claim

Regional context

Germany / EU

Applies equally.

Egypt

Applies equally.

• Antimicrobial use in food animals and antibiotic growth promoters
• Hormones in poultry, meat, milk and farmed fish
• Dioxins, PCBs and PFAS in eggs and other animal foods
• Heavy metals in fish
• Farmed fish (aquaculture): drugs, water source and controls
• Import controls and the meaning of RASFF notifications for Egyptian products

What applies in my country?

General scientific assessment

Mostly true Mostly true for typical fish-oil capsules, with exceptions for prescription high-dose EPA.

The following areas of food safety are relevant to this statement:

• Veterinary medicines and antibiotics
• Contaminants (heavy metals, PFAS, PCBs, dioxins, nitrate)
• Pathogens (Salmonella, Campylobacter, etc.)
• Animal husbandry and feed

Fish and seafood

Limits: legal rules describe what is allowed, not what every single food contains. Measurement data come from samples and are meaningful only together with their method details.

Country of residence or purchase Compare with another country

References

1. n-3 fatty acids and cardiovascular events after myocardial infarction.. Kromhout D et al.. N Engl J Med 2010 · PMID 20929341 · DOI 10.1056/NEJMoa1003603
2. Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer.. Manson JE et al.. N Engl J Med 2019 · PMID 30415637 · DOI 10.1056/NEJMoa1811403
3. Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus.. ASCEND Study Collaborative Group et al.. N Engl J Med 2018 · PMID 30146932 · DOI 10.1056/NEJMoa1804989
4. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial.. Nicholls SJ et al.. JAMA 2020 · PMID 33190147 · DOI 10.1001/jama.2020.22258
5. Effect of Long-Term Marine ɷ-3 Fatty Acids Supplementation on the Risk of Atrial Fibrillation in Randomized Controlled Trials of Cardiovascular Outcomes: A Systematic Review and Meta-Analysis.. Gencer B et al.. Circulation 2021 · PMID 34612056 · DOI 10.1161/CIRCULATIONAHA.121.055654
6. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.. Bhatt DL et al.. N Engl J Med 2019 · PMID 30415628 · DOI 10.1056/NEJMoa1812792
7. Effect of Omega-3 Dosage on Cardiovascular Outcomes: An Updated Meta-Analysis and Meta-Regression of Interventional Trials.. Bernasconi AA et al.. Mayo Clin Proc 2021 · PMID 32951855 · DOI 10.1016/j.mayocp.2020.08.034
8. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease.. Abdelhamid AS et al.. Cochrane Database Syst Rev 2020 · PMID 32114706 · DOI 10.1002/14651858.CD003177.pub5
9. Omega-3 supplementation and cardiovascular disease: formulation-based systematic review and meta-analysis with trial sequential analysis.. Rizos EC et al.. Heart 2021 · PMID 32820013 · DOI 10.1136/heartjnl-2020-316780